Compare · NVO vs PCSA
NVO vs PCSA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Processa Pharmaceuticals Inc. (PCSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PCSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $194.45B, about 33830.1x PCSA ($5.7M).
- Over the past year, NVO is down 41.4% and PCSA is down 68.1% - NVO leads by 26.7 points.
- PCSA has been more active in the news (10 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for PCSA).
- Company
- Novo Nordisk A/S
- Processa Pharmaceuticals Inc.
- Price
- $43.57-0.76%
- $2.10-7.28%
- Market cap
- $194.45B
- $5.7M
- 1M return
- -2.57%
- -30.00%
- 1Y return
- -41.38%
- -68.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 3
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PCSA
- Pres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,892 worth of shares (2,654 units at $2.22), increasing direct ownership by 25% to 13,412 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,465 units at $2.22), increasing direct ownership by 25% to 12,435 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (1,831 units at $2.22), increasing direct ownership by 20% to 11,007 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,702 worth of shares (2,118 units at $2.22), increasing direct ownership by 22% to 11,958 units (SEC Form 4)
- Pres. Research & Development Young David bought $4,590 worth of shares (1,786 units at $2.57), increasing direct ownership by 12% to 17,131 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,890 worth of shares (2,292 units at $2.57), increasing direct ownership by 27% to 10,758 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,129 units at $2.57), increasing direct ownership by 27% to 9,970 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,582 units at $2.57), increasing direct ownership by 21% to 9,176 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,701 worth of shares (1,829 units at $2.57), increasing direct ownership by 23% to 9,840 units (SEC Form 4)